JIUQUAN, China, Nov. 23, 2021 /PRNewswire/ -- Qilian
International Holding Group Limited (Nasdaq: QLI) (the "Company"),
a China-based pharmaceutical and
chemical products manufacturer, today announced that Gan Di Xin®
and Qilian Shan® Oxytetracycline, products of the Company's
subsidiary, Gansu Qilianshan Pharmaceutical Co., Ltd. ("Gansu
QLS"), have been included in the List for Development of Leading
Enterprises with Large Varieties and Brands of Pharmaceuticals of
Gansu Province (the "List"). The
List selects key medicines and medical devices with a goal of
facilitating the development and promotion of leading
pharmaceutical brands in Gansu
Province.
The List was issued by the Department of Industry and
Information Technology of Gansu
Province (the "Department") on October 13, 2021 with the release of the "Notice
of the General Office of the People's Government of Gansu Province on Policies and Measures to
Support the Development of Leading Enterprises with Large Varieties
and Brands of Pharmaceuticals of Gansu
Province". The Department has included a total of 55
medicines and medical devices from 27 enterprises, including Gan Di
Xin® and Qilian Shan® Oxytetracycline from the Company.
The List is a major strategic decision of the Gansu provincial government (the "Government")
as an effort to support the growth of local leading pharmaceutical
companies. The Government expects to promote the development of
local pharmaceutical industry, strengthen brand awareness for local
companies and position Gansu
province as a leading region for pharmaceutical industry through
cultivating large pharmaceutical enterprises, enhancing the
competitiveness of local pharmaceutical companies, and supporting
pharmaceutical companies in Gansu
province. The Government will include all the products on the List
into Gansu Province Reimbursement Drug List and support the
inclusion of all the products on the List in the National Essential
Medicines List and National Reimbursement Drug List in China.
The Qilian Shan® and Gan Di Xin® trademarks owned by Gansu QLS
are well-known domestic brands and have been favored by the market
for a long time. As a global producer, manufacturer, and supplier
of oxytetracycline, the Company's oxytetracycline meets the United
States Pharmacopeia (the "USP") quality standards and their
technical indicators have long been in the forefront of the
industry. Based on the recognized quality as well as strong
stability, coupled with efficient marketing methods, the Company's
oxytetracycline has obtained over 35% domestic market share. Gan Di
Xin® is a high-tech product independently developed by the Company
and its preparation method was granted a national invention patent.
Gan Di Xin® has been listed in China's State Category V New Drug with an
exclusive domestic production and is a well-known product in
Gansu Province and China.
The inclusion of Gansu QLS's Gan Di Xin® and Qilian Shan®
Oxytetracycline in the List affirms these products' leading
positions in the market and further enhances the Company's brand
awareness. The products, included in the List and Gansu Province
Reimbursement Drug List, and recommended to be included in the
National Essential Medicines List and National Reimbursement Drug
List, can be sold in hospitals of all types in Gansu province and hospitals across
China, thereby covering the entire
national market. These products also benefit from the national
medical insurance reimbursement policy, which is expected to
contribute to the Company's efforts to increase its product sales,
market share, operating income, and business performance.
Mr. Zhanchang Xin, Chairman and CEO of the Company, commented,
"We are excited to have Gansu QLS's Gan Di Xin® and Qilian Shan®
Oxytetracycline included in the List for Development of Leading
Enterprises with Large Varieties and Brands of Pharmaceuticals of
Gansu Province. This demonstrates
the Government's recognition of the value and quality of our
products and gives us a tremendous boost in our confidence to
continue researching and developing world class products. Looking
forward, we will continue to improve and leverage the advantages of
our brands such as Gansu QLS's Gan Di Xin® and Qilian Shan®
Oxytetracycline and other famous products to turn them into
world-renowned brands."
About Qilian International Holding Group Limited
Qilian International Holding Group Limited, headquartered in
Gansu, China, is a pharmaceutical
and chemical products manufacturer in China. It focuses on the development,
manufacture, marketing and sale of licorice products,
oxytetracycline products, traditional Chinese medicine derivatives
product, heparin product, sausage casings, and fertilizers. The
Company's products are sold in more than 20 provinces in
China. For more information, visit
the Company's website at http://ir.qlsyy.net/index.html or
http://qilianinternational.com/.
Forward-Looking Statements
This announcement contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All statements other than statements
of historical fact in this announcement are forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, financial
needs and the successful construction of the pig by-product
processing project facility. Investors can identify these
forward-looking statements by words or phrases such as "may,"
"will," "expect," "anticipate," "aim," "estimate," "intend,"
"plan," "believe," "potential," "continue," "is/are likely to" or
other similar expressions. The Company undertakes no obligation to
update forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company's registration statement and in its
other filings with the SEC.
For more information, please contact:
Qilian International Holding Group Limited
Email: ir@qlsyy.net
Ascent Investors Relations LLC
Tina Xiao
President
Phone: 917-609-0333
Email: tina.xiao@ascent-ir.com
View original
content:https://www.prnewswire.com/news-releases/qilian-international-holding-group-limited-announces-inclusion-of-gan-di-xin-and-qilian-shan-oxytetracycline-into-list-for-development-of-leading-enterprises-with-large-varieties-and-brands-of-pharmaceuticals-of-gansu-province-301430707.html
SOURCE Qilian International Holding Group Limited